William R. Ringo Sells 600 Shares of Five Prime Therapeutics, Inc. (FPRX) Stock
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total transaction of $27,198.00. Following the sale, the director now owns 600 shares of the company’s stock, valued at approximately $27,198. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) traded up $1.73 during midday trading on Friday, hitting $45.05. 507,620 shares of the stock were exchanged, compared to its average volume of 403,906.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The company had revenue of $7.80 million during the quarter, compared to analyst estimates of $8.32 million. During the same period in the previous year, the company earned ($0.49) EPS. The company’s quarterly revenue was down 16.1% compared to the same quarter last year. equities analysts predict that Five Prime Therapeutics, Inc. will post -5.5 EPS for the current year.
Several brokerages have recently issued reports on FPRX. Royal Bank Of Canada began coverage on shares of Five Prime Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $41.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $52.00 price objective (down from $55.00) on shares of Five Prime Therapeutics in a research note on Thursday, August 10th. Zacks Investment Research lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. BidaskClub lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a research note on Friday, September 22nd. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $54.83.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning lifted its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 54 shares during the last quarter. Rockefeller Financial Services Inc. acquired a new stake in shares of Five Prime Therapeutics during the second quarter worth about $210,000. Tudor Investment Corp ET AL lifted its position in shares of Five Prime Therapeutics by 56.8% during the first quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 2,910 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Five Prime Therapeutics during the third quarter worth about $341,000. Finally, Legal & General Group Plc lifted its position in shares of Five Prime Therapeutics by 39.2% during the first quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 2,583 shares in the last quarter. 84.01% of the stock is currently owned by institutional investors.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.